HomeNewscoronavirusHope in the air: Scientists decode how coronavirus molecules 'camouflage' in host cell

Hope in the air: Scientists decode how coronavirus molecules 'camouflage' in host cell

According to the study, published in the journal Nature Communications, the molecule nsp10 modifies the viral mRNAs (which are blueprints for producing proteins) to mimic host cell's own mRNAs.

July 26, 2020 / 21:01 IST

Scientists, including those of Indian-origin, have resolved the structure of a molecule which the novel coronavirus uses to make its genetic sequence seem like a part of the host's own, an advance that may lead to the development of new antiviral drugs against COVID-19. According to the study, published in the journal Nature Communications, the molecule nsp10 modifies the viral mRNAs (which are blueprints for producing proteins) to mimic host cell's own mRNAs.

The researchers from the The University of Texas Health Science Center at San Antonio (UT Health San Antonio) in the US said by enabling this modification, nsp10 protects the virus from host cell immune response.

"It's a camouflage. Because of the modifications, which fool the cell, the resulting viral messenger RNA is now considered as part of the cell's own code and not foreign," said Yogesh Gupta, a co-author of the study from UT Health San Antonio.

According to the researchers, deciphering the 3D structure of nsp16 paves the way for the design of new drugs against the novel coronavirus SARS-CoV-2, and other emerging coronavirus infections.

These drugs, Gupta said can be designed to inhibit nsp16 from making the modifications, so that the host immune system would pounce on the invading virus, recognising it as foreign.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"Yogesh's work discovered the 3D structure of a key enzyme of the COVID-19 virus required for its replication and found a pocket in it that can be targeted to inhibit that enzyme. This is a fundamental advance in our understanding of the virus," said study coauthor Robert Hromas.

Based on the findings, the researchers have suggested structural sites on the SARS-CoV-2 nsp10 molecule which they say can be targeted for antiviral development.

PTI
first published: Jul 26, 2020 08:25 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347